Biotech | May 12, 2022
First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
The company dispatched the first batch of essential medicines worth US $ 30,000 to Ukraine through its embassy in New Delhi
The facility is among 12 centres established worldwide, and the first in Asia
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Subscribe To Our Newsletter & Stay Updated
